Lee Eppstein
Chief Tech/Sci/R&D Officer at New Brunswick Scientific Co., Inc.
Profile
Lee Eppstein has worked as a Director at Antyra, Inc. and as a Vice President-Technology at New Brunswick Scientific Co., Inc.
Lee Eppstein active positions
| Companies | Position | Start |
|---|---|---|
New Brunswick Scientific Co., Inc.
 New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Chief Tech/Sci/R&D Officer | 2000-01-31 |
Antyra, Inc.
 Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
New Brunswick Scientific Co., Inc.
New Brunswick Scientific Co., Inc. Medical SpecialtiesHealth Technology New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ. | Health Technology |
Antyra, Inc.
Antyra, Inc. Pharmaceuticals: MajorHealth Technology Antyra, Inc. develops cancer therapeutics. Its products include lead programs, a program to generate and develop disease-specific therapeutics; oncology leads, such as IGF-1R Antagonist, which represent a clinical strategy for the treatment of pancreatic and other cancers; and ANT-G12, a technology that isolates cytotoxic peptimetics that bind to cell surface targets expressed in a disease-specific context. The company was founded by by John K. A. Prendergast and Arthur J. Blume in 1996 and is headquartered in Edison, NJ. | Health Technology |
- Stock Market
- Insiders
- Lee Eppstein
